大行評級|大摩:下調中國中藥目標價至4.6港元 評級下調至“與大市同步”
摩根士丹利發表報吿指,由於私有化在即,中國中藥自二月交易公佈以來的交易模式主要受交易可能性的影響。8月和9月的正面事件例如管理層評論及兩個先決條件的進展令股價更接近收購價。因此,目前股價與4.6港元的發售價間的差價有限,只有6%。而該股近期的反彈反映出投資者對交易實現的信心。該行指,考慮到中藥配方顆粒的進一步減價,該行將公司2024至2030年盈利預測下調3至15%,評級由“增持”下調至“與大市同步”,目標價由4.7港元降至4.6港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.